Abstract #3844

Deferiprone has a dose-dependent effect on liver iron concentration assessed by MRI

Antonella Meloni¹, Vincenzo Positano¹, Gianluca Valeri², Gennaro Restaino³, Chiara Tudisca⁴, Paolo Preziosi⁵, Elisabetta Chiodi⁶, Maria Giovanna Neri¹, Stefano Pulini⁷, Basilia Piraino⁸, Petra Keilberg¹, and Alessia Pepe¹

¹Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy, ²Azienda Ospedaliero-Universitaria Ospedali Riuniti "Umberto I-Lancisi-Salesi", Ancona, Italy, ³Fondazione di Ricerca e Cura "Giovanni Paolo II", Campobasso, Italy, ⁴Policlinico "Paolo Giaccone", Palermo, Italy, ⁵Policlinico “Casilino", Roma, Italy, ⁶Arcispedale “S. Anna”, Ferrara, Italy, ⁷Ospedale Civile “Spirito Santo”, Pescara, Italy, ⁸Policlinico "G. Martino", Messina, Italy

The aim of this multi-centre study was to retrospectively assess in thalassemia major (TM) if deferiprone (DFP) had a dose-dependent effect on liver iron concentration (LIC) assessed by quantitative magnetic resonance imaging (MRI). We found out that the percentage of patients that worsened their status was significantly higher in patients with ≤ 75 mg/kg/d than in patients with > 75 mg/kg/d (26.6% vs 7.7%; P=0.016). So, the worsening in MRI LIC can be prevented by increasing the dose of deferiprone above the widely used regimen of 75 mg/kg body weight.

This abstract and the presentation materials are available to members only; a login is required.

Join Here